C‐KIT inhibitors such as imatinib and nilotinib have been approved for gastrointestinal stromal tumors and have shown the efficacy of advanced melanomas with C‐KIT alterations in several clinical trials. Here, KIT is linked to gastrointestinal stromal tumor.